中聯(lián)重科案例分析

中聯(lián)重科案例分析2025/1/151）盈利指標(biāo)長(zhǎng)期在同行業(yè)的對(duì)應(yīng)指標(biāo)之上。2）穩(wěn)定的股利政策。ListingorNot?

GROUP3rd——TheanalysisontheprosandconsofacompanylistingbasedonYunnan-BaiyaoCo.,Ltd.2025/1/15contents1243

ThedisadvantagesoflistedcompanyThebenefitsoflistedcompanyBriefintroductionofthecompanyConclusion2025/1/15Yunnan-BaiyaoCo.,Ltd.2025/1/15云南白藥大事記From1971to20142025/1/15

1971云南白藥廠

1993年云南白藥實(shí)業(yè)有限公司。深圳證券交易所上市，股票發(fā)行價(jià)為3.38元/股。1996年云南白藥股份有限公司。實(shí)現(xiàn)云南白藥獨(dú)家生產(chǎn)經(jīng)營(yíng)

2008年產(chǎn)品收入額突破10億，股票市值達(dá)到27.87元/股。2014年總資產(chǎn)138.28億元，營(yíng)業(yè)收入86.27億元。FinancingForthemanagersandemployeesForthecooperaters2025/1/15BENEFITS2025/1/15Financing1.ThebriefintroductionoftheIPO.2.Goingpublicproviderefinancingsources.3.Goingpublicisbetterfortherealizationofthedevelopmentstrategies.4.Goingpublicbringstheimprovementofthecorporateimage5.Goingpublicisgoodforimprovingtheinvestors’confidence19932000萬400萬6700萬3.38元/股時(shí)間資金來源實(shí)際募集資金（人民幣元）發(fā)行費(fèi)用（人民幣元）貨幣募集資金（人民幣元）1996-01-13配股19480000742168202221682000-01-17配股71103799.76235871073462509.762008-12-30增發(fā)13639840002951600013935000002025/1/15Forthemanagersandemployees1.LessrestrictionandHigherflexibility.2.Improvetheattractionofthecorporateandthemotivationoftheemployees.3.Improvethequalityandenrichthekindsoftheproducts.4.Strengthentheloyaltyoftheemployersandthestockholders,cutdowntheprobabilityofthememberchanges.2025/1/15Forthecooperaters1.Enlargewealth.2.Easierforthestockholderstogettheirmoneyback.指標(biāo)1993199219911993每股凈資產(chǎn)2.051.121.1730%每股收益0.23?0.20?0.14?15%每股紅利0.08

股東權(quán)益比率93?5655????66股東權(quán)益1642263511032596368%Thebadinfluencesthepublicexposuremakes.Excessiveattentiontotheshort-termperformances.Highcostforgoingpublic.2025/1/15DISADVANTAGESTheintensificationtothecontradictionoftheseniorexecutiveteam.2025/1/15Thebadinfluencesthepublicexposuremakes.1.Incompleteexposurecausessocialdisturbance.2.Thebadinfluencethepublicexposuremakesforthemarketoperatingofthecorporate.3.Conclusion2025/1/15Excessiveattentiontotheshort-termperformances.2025/1/15Highcostforgoingpublic.財(cái)務(wù)顧問費(fèi)用輔導(dǎo)費(fèi)用承銷費(fèi)用審計(jì)及驗(yàn)資費(fèi)用律師費(fèi)用評(píng)估費(fèi)用路演費(fèi)用保薦費(fèi)用上市初費(fèi)/年費(fèi)股票登記費(fèi)信息披露費(fèi)2025/1/15Theintensificationtothecontradictionoftheseniorexecutiveteam.1.Theinsufficientsharesbelongtoth